Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F24%3AE0110974" target="_blank" >RIV/00843989:_____/24:E0110974 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/24:A2503AJR

Result on the web

<a href="https://link.springer.com/article/10.1007/s00262-024-03704-7" target="_blank" >https://link.springer.com/article/10.1007/s00262-024-03704-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00262-024-03704-7" target="_blank" >10.1007/s00262-024-03704-7</a>

Result language

angličtina

Original language name

Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms

Original language description

Background: Advancements in immunotherapeutic approaches only had a modest impact on the therapy of lung neuroendocrine neoplasms (LNENs). Our multicenter study aimed to investigate the expression patterns of novel immunotherapy targets in intermediate- and high-grade LNENs. Methods: The expressions of V-domain Ig suppressor of T cell activation (VISTA), OX40L, Glucocorticoid-induced TNF receptor (GITR), and T cell immunoglobulin and mucin domain 3 (TIM3) proteins were measured by immunohistochemistry in surgically resected tumor samples of 26 atypical carcinoid (AC), 49 large cell neuroendocrine lung cancer (LCNEC), and 66 small cell lung cancer (SCLC) patients. Tumor and immune cells were separately scored. Results: Tumor cell TIM3 expression was the highest in ACs (p < 0.001), whereas elevated tumor cell GITR levels were characteristic for both ACs and SCLCs (p < 0.001 and p = 0.011, respectively). OX40L expression of tumor cells was considerably lower in ACs (vs. SCLCs; p < 0.001). Tumor cell VISTA expression was consistently low in LNENs, with no significant differences across histological subtypes. ACs were the least immunogenic tumors concerning immune cell abundance (p < 0.001). Immune cell VISTA and GITR expressions were also significantly lower in these intermediate-grade malignancies than in SCLCs or in LCNECs. Immune cell TIM3 and GITR expressions were associated with borderline prognostic significance in our multivariate model (p = 0.057 and p = 0.071, respectively). Conclusions: LNEN subtypes have characteristic and widely divergent VISTA, OX40L, GITR, and TIM3 protein expressions. By shedding light on the different expression patterns of these immunotherapy targets, the current multicenter study provides support for the future implementation of novel immunotherapeutic approaches.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancer immunology, immunotherapy

ISSN

0340-7004

e-ISSN

1432-0851

Volume of the periodical

73

Issue of the periodical within the volume

article 114

Country of publishing house

DE - GERMANY

Number of pages

15

Pages from-to

1-15

UT code for WoS article

001225923900001

EID of the result in the Scopus database

2-s2.0-85191723943